An open-label study to evaluate the safety and tolerability of 12 weeks of treatment with oral REN001 in subjects with long-chain fatty acid oxidation disorders (LC-FAOD) Vockley et al., INFORM 2022
A prospective, multicenter, non-interventional study to investigate the disease characteristics of adult patients with long-chain fatty acid oxidation disorders: The FORWARD study Gillingham et al., INFORM 2022
REN001, a novel peroxisome proliferator-activated receptor delta (PPARδ)agonist, improves gait in patients with primary mitochondrial myopathy after 12-weeks Alcock et al., Neuromuscular Medicine, 2022
Characterization of Fatigue in Primary Mitochondrial Myopathy: Findings from a Qualitative Interview Study Karaa et al., UMDF Mitochondrial Medicine, 2021
